Inhibitors of Bruton's tyrosine kinase
View Patent ↗Disclosed herein are amido compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
1. A kinase inhibitor according to formula (IIIa), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), (IIIg), or (IIIh):
wherein R 3 is independently H, alkyl, CN, or cycloalkyl;
each R 4 is independently H, halo, hydroxyl, CN, substituted or unsubstituted alkyl, substituted or unsubstituted amino, substituted or unsubstituted alkoxy, substituted or unsubstituted amido, substituted or unsubstituted sulfonyl, substituted or unsubstituted carboxy, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and each n is independently 0, 1, or 2; or a pharmaceutically acceptable salt, or solvate thereof.
2. The kinase inhibitor according to claim 1 , wherein the compound is according to formula (IIIe), (IIIf), (IIIg) or (IIIh):
wherein R 3 and R 4 are as in claim 1 ; or a pharmaceutically acceptable salt, or solvate thereof.
3. The kinase inhibitor according to claim 1 , wherein the compound is according to formula (IVa), (IVb), (IVc) or (IVd):
wherein R 3 , and R 4 are as in claim 1 ; or a pharmaceutically acceptable salt, or solvate thereof.
4. The kinase inhibitor according to claim 1 , wherein the compound is according to formula (Va), (Vb), (Vc) or (Vd):
wherein R 3 and R 4 are as in claim 1 ; or a pharmaceutically acceptable salt, or solvate thereof.
5. The kinase inhibitor according to any one of claim 2 , 3 , or 4 , wherein R 3 is C 1 -C 4 alkyl.
6. The kinase inhibitor according to any one of claim 2 , 3 , or 4 , wherein R 3 is H, Me, Et, n-Pr, or i-Pr.
7. The kinase inhibitor according to any one of claim 2 , 3 , or 4 , wherein R 3 is cycloalkyl.
8. The kinase inhibitor according to any one of claim 2 , 3 , or 4 , wherein R 3 is cyclopropyl.
9. The kinase inhibitor according to claim 1 , wherein the compound is according to formula (VIa), (VIb), (VIc), or (VId):
wherein R 4 is as in claim 1 ; or a pharmaceutically acceptable salt, or solvate thereof.
10. The kinase inhibitor according to claim 1 , wherein the compound is according to formula (VIe), (VIf), (VIg) or (VIh):
wherein R 4 is as in claim 1 ; or a pharmaceutically acceptable salt, or solvate thereof.
11. The kinase inhibitor according to claim 1 , wherein the compound is according to formula (VIIa), (VIIb), (VIIc), or (VIId):
wherein R 4 is as in claim 1 ; or a pharmaceutically acceptable salt, or solvate thereof.
12. The kinase inhibitor according to any one of claim 9 , 10 , or 11 , wherein R 4 is H, Me, Et, n-Pr, i-Pr, CF 3 or CN.
13. The kinase inhibitor according to claim 1 , wherein the compound is according to formula (VIIIa), (VIIIb), (VIIIc) or (VIIId):
or a pharmaceutically acceptable salt, or solvate thereof.
14. The kinase inhibitor according to claim 1 , wherein the compound is according to formula (VIIIe), (VIIIf), (VIIIg) or (VIIIh):
or a pharmaceutically acceptable salt, or solvate thereof.
15. The kinase inhibitor according to claim 1 , wherein the compound is according to formula (IXa), (IXb), (IXc) or (IXd):
or a pharmaceutically acceptable salt, or solvate thereof.
16. The kinase inhibitor according to claim 1 , wherein the compound is according to formula (Xa), (Xb), (Xc) or (Xd):
or a pharmaceutically acceptable salt, or solvate thereof.
17. The kinase inhibitor according to claim 1 , wherein the compound is according to formula (Xe), (Xf), (Xg), or (Xh):
or a pharmaceutically acceptable salt, or solvate thereof.
18. The kinase inhibitor according to claim 1 , wherein the compound is according to formula (XIa), (XIb), (XIc), or (XId):
or a pharmaceutically acceptable salt, or solvate thereof.
19. A kinase inhibitor which is a compound selected from:
(R)-4-(4-amino-1-(1-but-2-ynoylpyrrolidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide;
(R)-4-(4-amino-1-(1-but-2-ynoylpyrrolidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(4-methylpyridin-2-yl)benzamide;
(R)-4-(4-amino-1-(1-but-2-ynoylpyrrolidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(pyridin-2-yl)benzamide;
(R)-4-(4-amino-1-(1-but-2-ynoylpyrrolidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(4-isopropylpyridin-2-yl)benzamide;
(R)-4-(4-amino-1-(1-but-2-ynoylpyrrolidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(4-cyanopyridin-2-yl)benzamide;
(R)-4-(4-amino-1-(1-but-2-ynoylpiperidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(4-isopropylpyridin-2-yl)benzamide;
(R)-4-(4-amino-1-(1-pent-2-ynoylpyrrolidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(4-methylpyridin-2-yl)benzamide;
(R)-4-(4-amino-1-(1-(3-cyclopropylpropioloyl)pyrrolidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(4-me thylpyridin-2-yl)benzamide;
(R)-4-(4-amino-1-(1-but-2-ynoylpyrrolidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(4-propylpyridin-2-yl)benzamide;
(R)-4-(4-amino-1-(1-but-2-ynoylpiperidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(pyridin-2-yl)benzamide;
(R)-4-(4-amino-1-(1-but-2-ynoylpiperidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(4-methylpyridin-2-yl)benzamide;
(R)-4-(4-amino-1-(1-but-2-ynoylpiperidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide;
(R)-4-(4-amino-1-(1-but-2-ynoylpiperidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(4-propylpyridin-2-yl)benzamide;
(R)-4-(4-amino-1-(1-but-2-ynoylpiperidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(4-cyanopyridin-2-yl)benzamide;
(R)-4-(4-amino-1-(1-but-2-ynoylpyrrolidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(thiazol-2-yl)benzamide;
(R)-4-(4-amino-1-(1-but-2-ynoylpiperidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(thiazol-2-yl)benzamide;
(R)-4-(4-amino-1-(1-but-2-ynoylpiperidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(5-methylthiazol-2-yl)benzamide;
(R)-4-(1-(1-acryloylpyrrolidin-3-yl)-4-amino-1H-pyrazolo pyrimidin-3-yl)-N-(4-methylpyridin-2-yl)benzamide;
(R)-4-(1-(1-acryloylpyrrolidin-3-yl)-4-amino-1H-pyrazolo pyrimidin-3-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide;
(R)-4-(1-(1-acryloylpyrrolidin-3-yl)-4-amino-1H-pyrazolo pyrimidin-3-yl)-N-(pyridin-2-yl)benzamide;
(R)-4-(1-(1-acryloylpyrrolidin-3-yl)-4-amino-1H-pyrazolo pyrimidin-3-yl)-N-(4-isopropylpyridin-2-yl)benzamide;
R)-4-(1-(1-acryloylpyrrolidin-3-yl)-4-amino-1H-pyrazolo pyrimidin-3-yl)-N-(4-cyanopyridin-2-yl)benzamide;
(R)-4-(1-(1-acryloylpiperidin-3-yl)-4-amino-1H-pyrazolo pyrimidin-3-yl)-N-(pyridin-2-yl)benzamide;
(R)-4-(1-(1-acryloylpiperidin-3-yl)-4-amino-1H-pyrazolo pyrimidin-3-yl)-N-(4-methylpyridin-2-yl)benzamide;
(R)-4-(1-(1-acryloylpiperidin-3-yl)-4-amino-1H-pyrazolo pyrimidin-3-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide;
(R)-4-(1-(1-acryloylpiperidin-3-yl)-4-amino-1H-pyrazolo pyrimidin-3-yl)-N-(4-isopropylpyridin-2-yl)benzamide;
(R)-4-(1-(1-acryloylpiperidin-3-yl)-4-amino-1H-pyrazolo pyrimidin-3-yl)-N-(4-cyanopyridin-2-yl)benzamide;
(R)-4-(1-(1-acryloylpyrrolidin-3-yl)-4-amino-1H-pyrazolo pyrimidin-3-yl)-N-(4-propylpyridin-2-yl)benzamide;
(R)-4-(1-(1-acryloylpiperidin-3-yl)-4-amino-1H-pyrazolo pyrimidin-3-yl)-N-(4-propylpyridin-2-yl)benzamide;
(R,E)-4-(4-amino-1-(1-but-2-enoylpyrrolidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(4-methylpyridin-2-yl)benzamide;
(R)-4-(4-amino-1-(1-(3-methylbut-2-enoyl)pyrrolidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(4-methylpyridin-2-yl)benzamide;
(R)-4-(1-(1-acryloylpyrrolidin-3-yl)-4-amino-1H-pyrazolo pyrimidin-3-yl)-N-(5-methylthiazol-2-yl)benzamide;
(R)-4-(1-(1-acryloylpyrrolidin-3-yl)-4-amino-1H-pyrazolo pyrimidin-3-yl)-N-(thiazol-2-yl)benzamide;
4-(4-amino-1-((1R,4R)-4-but-2-ynamidocyclohexyl)-1H-pyrazolo pyrimidin-3-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide;
4-(1-((1R,4R)-4-acrylamidocyclohexyl)-4-amino-1H-pyrazolo pyrimidin-3-yl)-N-(4-methylpyridin-2-yl)benzamide;
4-(4-amino-1-((1R,4R)-4-but-2-ynamidocyclohexyl)-1H-pyrazolo pyrimidin-3-yl)-N-(pyridin-2-yl)benzamide;
4-(4-amino-1-((1R,4R)-4-but-2-ynamidocyclohexyl)-1H-pyrazolo pyrimidin-3-yl)-N-(4-methylpyridin-2-yl)benzamide;
4-(4-amino-1-((1R,4R)-4-but-2-ynamidocyclohexyl)-1H-pyrazolo pyrimidin-3-yl)-N-(4-isopropylpyridin-2-yl)benzamide;
4-(4-amino-1-((1R,4R)-4-but-2-ynamidocyclohexyl)-1H-pyrazolo pyrimidin-3-yl)-N-(4-cyanopyridin-2-yl)benzamide;
4-(4-amino-1-((1R,4R)-4-but-2-ynamidocyclohexyl)-1H-pyrazolo pyrimidin-3-yl)-N-(5-methylthiazol-2-yl)benzamide;
4-(4-amino-1-((1R,4R)-4-but-2-ynamidocyclohexyl)-1H-pyrazolo pyrimidin-3-yl)-N-(thiazol-2-yl)benzamide;
4-(1-((1R,4R)-4-acrylamidocyclohexyl)-4-amino-1H-pyrazolo pyrimidin-3-yl)-N-(thiazol-2-yl)benzamide;
(R,E)-4-(4-amino-1-(1-pent-2-enoylpyrrolidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(4-methylpyridin-2-yl)benzamide;
(R)-4-(4-amino-1-(1-methacryloylpyrrolidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(4-methylpyridin-2-yl)benzamide;
(R,Z)-4-(4-amino-1-(1-(2-methylbut-2-enoyl)pyrrolidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(4-me thylpyridin-2-yl)benzamide;
(R)-4-(4-amino-1-(1-(2-cyano-3-methylbut-2-enoyl)pyrrolidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(4-methylpyridin-2-yl)benzamide;
(R)-4-(4-amino-1-(1-(4-hydroxybut-2-ynoyl)pyrrolidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide;
(R)-4-(4-amino-1-(1-(4-methoxybut-2-ynoyl)pyrrolidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide; and
(R)-4-(4-amino-1-(1-(1-cyanocyclopropanecarbonyl)pyrrolidin-3-yl)-1H-pyrazolo pyrimidin-3-yl)-N-(pyridin-2-yl)benzamide; or
a solvate or a pharmaceutically acceptable salt thereof.
20. A pharmaceutical composition comprising a kinase inhibitor of claim 1 ; or a pharmaceutically acceptable salt, or solvate; and a pharmaceutically acceptable excipient.